These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

17 related articles for article (PubMed ID: 2138904)

  • 1. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
    Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
    Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone in plasma by solid-phase extraction and high-performance liquid chromatography.
    Betteridge RF; Bosanquet AG; Hunt P; Gilby ED
    J Chromatogr; 1988 Nov; 432():352-7. PubMed ID: 3220904
    [No Abstract]   [Full Text] [Related]  

  • 3. Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatography.
    Bosanquet AG; McLoughlin SB
    Invest New Drugs; 1985; 3(1):43-50. PubMed ID: 3838738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a sensitive solid-phase extraction and high-performance liquid chromatographic assay for the novel bio-reductive anti-tumor agent RH1 in human and mouse plasma.
    Khan P; Abbas S; Hargreaves RH; Caffrey R; Megram V; McGown A
    J Chromatogr B Biomed Sci Appl; 1999 Jun; 729(1-2):287-95. PubMed ID: 10410954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diaziquone, 2,5-diaziridinyl-3,6-biscarboethoxyamino-1,4-benzoquinone, plasma and cerebrospinal fluid kinetics.
    Bachur NR; Collins JM; Kelley JA; Van Echo DA; Kaplan RS; Whitacre M
    Clin Pharmacol Ther; 1982 May; 31(5):650-5. PubMed ID: 7075113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The reduction of anti-tumour diaziridinyl benzoquinones.
    Butler J; Hoey BM; Lea JS
    Biochim Biophys Acta; 1987 Aug; 925(2):144-9. PubMed ID: 3040109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZG, NSC 224070) during a phase I clinical trial.
    Betteridge RF; Bosanquet AG; Gilby ED
    Eur J Cancer; 1990 Feb; 26(2):107-12. PubMed ID: 2138904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism(s) of bioreductive activation. The example of diaziquone (AZQ).
    Gutierrez PL
    Free Radic Biol Med; 1989; 6(4):405-45. PubMed ID: 2651223
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.